Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such as digital PCR and extraction systems, and PCR kits; urinalysis analyzer systems and semi-automatic urine analyzers; and hemostasis solutions, including coagulation and semi-automatic coagulation analyzers. It also provides clinical chemistry products, such as glycohemoglobin and protein analyzer, biochemistry systems, and chemistry regents; blood group product solutions; and pathology solutions, such as a liquid-based cytology processing system technologies. In addition, the company offers Mike Smart Lab, a patient-centered medical laboratory system solution based on automation and digital intelligence. Maccura Biotechnology Co.Ltd was founded in 1994 and is headquartered in Chengdu, China.
Research context
Maccura Biotechnology Co.Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Maccura Biotechnology Co.Ltd is currently in a long term downtrend where the price is trading 13.0% below its 200 day moving average.
From a valuation standpoint, the stock is 29.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.8.
Maccura Biotechnology Co.Ltd's total revenue rose by 23.1% to $1B since the same quarter in the previous year.
Its net income has increased by 130.3% to $256M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.4% to $201M since the same quarter in the previous year.
Based on the above factors, Maccura Biotechnology Co.Ltd gets an overall score of 3/5.